APA (7th ed.) Citation

Scheid, J. F., Cunningham-Bussel, K., Kim, N., Agarwal, S., Nieddu, G., Cote, J., . . . Robbins, J. A. (2025). Safety, pharmacokinetics, and pharmacodynamics of MK-6194, an IL-2 mutein designed to selectively activate regulatory T cells: Single ascending dose and multiple ascending dose trial data. ImmunoHorizons, 9(5), . https://doi.org/10.1093/immhor/vlaf005

Chicago Style (17th ed.) Citation

Scheid, Johannes F., et al. "Safety, Pharmacokinetics, and Pharmacodynamics of MK-6194, an IL-2 Mutein Designed to Selectively Activate Regulatory T Cells: Single Ascending Dose and Multiple Ascending Dose Trial Data." ImmunoHorizons 9, no. 5 (2025). https://doi.org/10.1093/immhor/vlaf005.

MLA (9th ed.) Citation

Scheid, Johannes F., et al. "Safety, Pharmacokinetics, and Pharmacodynamics of MK-6194, an IL-2 Mutein Designed to Selectively Activate Regulatory T Cells: Single Ascending Dose and Multiple Ascending Dose Trial Data." ImmunoHorizons, vol. 9, no. 5, 2025, https://doi.org/10.1093/immhor/vlaf005.